Researchers from the Cancer Center of the University of Texas MD Anderson will present new data at the annual meeting of the American Radiation Company (ASTRO) 2025, proving that stereotactic body radiotherapy (SBRT) and surgery have achieved similar surgery Radiation offering quality-from-L-LISTIVE Benefits. These findings will be presented on September 29 by Joe Chang, MD, Ph.D., Professor of Oncology and Troy Kleber, MD, resident.
In an average monitoring of 8.3 years, total survival rates were 69% for the SBRT team and 66% for the surgery group, a difference that was not statistically significant. Survival rates for lung cancer and survival rates without repetition were also similar. Although the data shows a higher rate of acute complication caused by surgery, the quality of life research for patients in 10 years was similar. Chang and Kleber shared additional knowledge below.
What are the key findings presented?
“The most important finding is that SBRT and surgery had similar 10 years of results, reinforcing the original five -year data we have previously presented from this test. Complications,” Chang said.
What are the advantages of SBRT for surgery for patients?
“SBRT is a specific type of radiotherapy that precisely targets tumors with very high doses of radiation. It is also known as stereotactic body radiation (SABR). The first major advantage is simply that many patients are not eligible for surgery for various possible reasons. A factor is age, as many elderly patients are at a much greater risk for surgery complications, so a non -invasive option is immediately an advantage for these patients. Another advantage is an easier recovery process so that patients treated with SBRT generally less financial pressure than those undergoing surgery, “Kleber said.
Does this indicate that SBRT should be the choice for all patients with lung cancer who are not microcellular stages?
“No, but it emphasizes the importance of a multi -scientific care team to examine all options for their patients, for example, for patients whose tumors are more complex, larger or in some areas, surgery remains the best treatment option.
What methods were used in the study?
This test compared 80 patients undergoing SBRT treatment at 80 surgery. Registered patients had tumors less than three inches, with no lymph nodes and non -remote metastases. The surgical team received a video-hypocurrent thoracoscopic lobectomy and removal of the medullary lymph nodes.
